Saliva testing

Afero partners with Therma Bright to make AcuVid™ COVID-19 Rapid Antigen Saliva Test smart-enabled

Retrieved on:

Wednesday, April 28, 2021

Medical tests, Branches of biology, Life sciences, Biology, Medical terminology, Immunologic tests, Chromatography, Molecular biology, Rapid antigen test, Saliva testing

b'LOS ALTOS, Calif., April 28, 2021 /PRNewswire-PRWeb/ --Afero has entered into an agreement with Therma Bright TSXV(THRM.V), developer of the AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, to bring greater innovation, security and tracking to its 15-minute COVID-19 rapid antigen screening solution.

Key Points:

b'LOS ALTOS, Calif., April 28, 2021 /PRNewswire-PRWeb/ --Afero has entered into an agreement with Therma Bright TSXV(THRM.V), developer of the AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, to bring greater innovation, security and tracking to its 15-minute COVID-19 rapid antigen screening solution.
With the secure Afero Cloud, AcuVid test status is tracked and managed on a real-time basis for many millions of tests deployed around the world.
The Afero encrypted QR Code solution will be embedded on each Acuvid Rapid Antigen Test for both enterprise and consumer use.
"Therma Bright\'s AcuVid COVID-19 Rapid Antigen Test, powered by Afero, is measurable progress towards enabling everyone on the planet to be able to take a secure, simple, reliable saliva-based test.

Autism Biomarkers Could Save Billions in Healthcare Costs According to Recent Study

Retrieved on:

Thursday, April 22, 2021

Branches of biology, Clinical medicine, Psychiatric diagnosis, Medicine, Autism, Pervasive developmental disorders, Communication disorders, Autism spectrum, Developmental psychology, Saliva testing, Biomarker

b'SYRACUSE, N.Y., April 22, 2021 /PRNewswire/ --The use of accurate biomarkers for detecting autism spectrum disorder (ASD) could result in saving billions of dollars in healthcare costs, according to a paper recently published in the journal Autism Research .

Key Points:

b'SYRACUSE, N.Y., April 22, 2021 /PRNewswire/ --The use of accurate biomarkers for detecting autism spectrum disorder (ASD) could result in saving billions of dollars in healthcare costs, according to a paper recently published in the journal Autism Research .
Unfortunately, this high rate of autism in the US, when combined with a relatively small number of specialists trained to make the diagnosis, has resulted in long wait times for families to receive an autism evaluation.
The study focused on two recently researched and published biomarker technologies: a molecular saliva test and a remote eye gazing tracking technology.
Recently, it has leveraged its expertise in RNA analysis to co-develop a COVID-19 saliva test with SUNY Upstate Medical University.

First Pilot Program of Easy Saliva Test for Weekly Monitoring of Viral Infection and Other Health Risks Launched in the US

Retrieved on:

Tuesday, April 13, 2021

Medical tests, Medicine, Clinical medicine, Health, Infectious diseases, Zoonoses, Saliva testing, Virus, Saliva, Computer virus

Mr. Leung then focused on identifying other data points that could enhance their program and settled on saliva as a critical focus.

Key Points:

Mr. Leung then focused on identifying other data points that could enhance their program and settled on saliva as a critical focus.
This idea is exciting, and we have moved forward seeking potential US-based partners.
"\nCOVID - 19 has escalated some of their research because, as with any disease or foreign intruder in our bodies, saliva shows the body\'s response to viruses.
eNano\'s saliva test can isolate data (in a particular number range) that shows something like a virus is active in our system.

Global Digital POCT (Point-of-Care Testing) Market Report 2021: Growth Opportunity in Saliva-based Rapid Testing for COVID-19 - ResearchAndMarkets.com

Retrieved on:

Thursday, March 11, 2021

Pharmaceutical, Health, Medical devices, Medicine, Medical tests, Clinical medicine, Medical terminology, Point-of-care testing, Diabetes, Medical monitoring, Blood glucose monitoring, Saliva testing, Diabetes management, COVID-19 testing, Glucose

The "Smartphone-based Saliva Testing and Self-monitoring of Blood Glucose Driving the Digital POCT Market" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Smartphone-based Saliva Testing and Self-monitoring of Blood Glucose Driving the Digital POCT Market" report has been added to ResearchAndMarkets.com's offering.
Smartphone-based devices and associated tools are becoming the ideal next-generation point-of-care testing (POCT) solutions for in vitro diagnostics.
The World Health Organization (WHO) has endorsed POCT as the topmost research priority in response to the COVID-19 outbreak.
Smartphone-based POCT Market by Testing Site, US and EU5, 2020-2025
Growth Opportunity 1 - Saliva-based Rapid Testing for COVID-19, 2021
Growth Opportunity 2 - Self-monitoring Blood Glucose Test Systems for Diabetes Management, 2021
Growth Opportunity 3 - In-car Health and Wellness Creates a New Diagnostic Testing Site, 2021

Clinical Reference Laboratory Makes First At-Home COVID-19 Saliva Test Available Through Walgreens Find Care®

Retrieved on:

Wednesday, February 24, 2021

Life sciences, Articles, Branches of biology, Biotechnology, Laboratory techniques, Molecular biology, Medical tests, Emergency Use Authorization, Food and Drug Administration, Walgreens, Reverse transcription polymerase chain reaction, Saliva testing

DEERFIELD, Ill.and LENEXA, Kan., Feb. 24, 2021 /PRNewswire/ -- Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., and Walgreens today announced that the FDA-authorized CRL Rapid Response COVID-19 Saliva Test is now available through Walgreens Find Care , a digital health platform available on the Walgreens app and Walgreens.com.

Key Points:

DEERFIELD, Ill.and LENEXA, Kan., Feb. 24, 2021 /PRNewswire/ -- Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., and Walgreens today announced that the FDA-authorized CRL Rapid Response COVID-19 Saliva Test is now available through Walgreens Find Care , a digital health platform available on the Walgreens app and Walgreens.com.
"Testing continues to be a critical tool to keep Americans safe even as the vaccine rolls out," said Robert Thompson, CEO at Clinical Reference Laboratory.
"The HealthConfirm-branded COVID-19 Saliva Test uses Clinical Reference Laboratory's PCR testing technology, which demonstrated highly accurate results with 100 percent sensitivity and specificity in its FDA EUA filing.
Clinical Reference Laboratory received FDAEmergency Use Authorization (EUA) for its saliva-based COVID-19 RT-PCR test in July 2020.

GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests

Retrieved on:

Thursday, February 18, 2021

Johns Hopkins University, Saliva testing, Johns Hopkins Bloomberg School of Public Health, Health sciences, Group B streptococcal infection

NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary health practitioners, today announced the execution of a sponsored research agreement with Johns Hopkins Bloomberg School of Public Health to accelerate development of next-generationsaliva-baseddiagnostic tests.

Key Points:

NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary health practitioners, today announced the execution of a sponsored research agreement with Johns Hopkins Bloomberg School of Public Health to accelerate development of next-generationsaliva-baseddiagnostic tests.
The sponsored research agreement marks a collaboration between GBS Inc. and the Johns Hopkins Environmental Health Microbiology and Immunology Laboratory in the Department of Environmental Health and Engineering at the Johns Hopkins Bloomberg School of Public Health,and the labs Salivary Biomarkers and Infectious Diseases Program.
The research will inform GBS Inc.s commercialization strategy for two non-invasive, rapid POC diagnostic tests already in development: the SARS-CoV-2 Antibody Biosensor and, for people living with diabetes, the Saliva Glucose Biosensor.
Research led by the Johns Hopkins Environmental Health Microbiology and Immunology Laboratory in 2020 demonstrated the potential utility of saliva testing in large-scalesero-surveillance to address key public health and clinical prioritiesrelated to the COVID-19 pandemic.

Patients Choice Laboratories Launches PCR Saliva COVID-19 Test

Retrieved on:

Tuesday, February 16, 2021

Branches of biology, Biology, Life sciences, Medical tests, Biotechnology, Laboratory techniques, Molecular biology, Saliva testing, Polymerase chain reaction, Coronavirus disease, Saliva, COVID-19 testing

INDIANAPOLIS, Feb. 16, 2021 /PRNewswire/ --Patients Choice Laboratories (PCL), a leading life sciences company, is proud to offer its COVID+ Saliva Test, a COVID-19 saliva test by PCR.

Key Points:

INDIANAPOLIS, Feb. 16, 2021 /PRNewswire/ --Patients Choice Laboratories (PCL), a leading life sciences company, is proud to offer its COVID+ Saliva Test, a COVID-19 saliva test by PCR.
"Our COVID+ Saliva Test by PCR with same day turnaround time is an accurate, swift and noninvasive solution designed for self-collection.
"Omni International is happy to assist Patients Choice Laboratories with its new COVID+ Saliva Test that is a PCR SAR-CoV-2 saliva-based test.
Patients Choice Laboratories, based in Indianapolis, Indiana, is a leading provider of comprehensivelaboratory testing services throughout the United States.Since 2013, Patients Choice Laboratories has served patients and providers with a focus on providing fast, accurate and reliable results.

Canary Health Technologies Submits a Revolutionary 25-Second, 98% Sensitivity, Digital COVID-19 Saliva Test to the FDA

Retrieved on:

Tuesday, February 9, 2021

Medicine, Medical tests, Clinical medicine, Health sciences, Medical terminology, COVID-19 testing, Rapid antigen test, Saliva testing, Coronavirus disease

CLEVELAND, Feb. 9, 2021 /PRNewswire/ -- Med tech company Canary Health Technologies, Inc. has developed a 25-second COVID-19 test, delivering real-time results with 98% sensitivity and 100% specificity.

Key Points:

CLEVELAND, Feb. 9, 2021 /PRNewswire/ -- Med tech company Canary Health Technologies, Inc. has developed a 25-second COVID-19 test, delivering real-time results with 98% sensitivity and 100% specificity.
Suitable for self-testing, Canary's Pelican COVID-19 Ultra-Rapid Mobile Test (Pelican CV-19 Mobile), a digital antigen test, is designed for testing inside homes, businesses, and clinics.
This antigen saliva test utilizes cutting-edge technology with dual targeting to reduce errors, delivering results on an easily readable LCD display.
The cloud-based testing system is HIPPA compliant which protects the integrity of protected health information of users.

OraSure Subsidiary DNA Genotek’s OMNIgene®·ORAL Saliva Collection Device Receives Health Canada Authorization for use in COVID-19 Testing

Retrieved on:

Thursday, January 28, 2021

Medicine, COVID-19 testing, Medical tests, Clinical medicine, Coronavirus disease, Health sciences, Saliva testing, Color Genomics

Diagnostic labs, provincial and territory health authorities and COVID-19 test kit providers in Canada now have access to a non-invasive and painless saliva collection device to facilitate expansion of their COVID-19 testing programs.

Key Points:

Diagnostic labs, provincial and territory health authorities and COVID-19 test kit providers in Canada now have access to a non-invasive and painless saliva collection device to facilitate expansion of their COVID-19 testing programs.
Those adding saliva to their workflow must validate the use of the OMNIgeneORAL with their assay prior to SARS-CoV-2 testing in accordance with applicable regulations.
Providing labs, health units and test kit providers with technology like saliva collection for use at home or supervised by healthcare providers is critical in the fight against COVID-19.
This authorization could be transformative for public health efforts in Canada and is an important tool to increase access to testing.

Novel SARS CoV-2 Saliva Collection Devices Address COVID-19 Testing Challenges, Improving Lab Efficiency and PCR Test Performance

Retrieved on:

Tuesday, January 26, 2021

GenTegra, LLC, a Pleasanton, California-based company , announced today a study on the development and characterization of two novel COVID-19 saliva sample collection tube devices.

Key Points:

GenTegra, LLC, a Pleasanton, California-based company , announced today a study on the development and characterization of two novel COVID-19 saliva sample collection tube devices.
https://www.medrxiv.org/content/10.1101/2021.01.20.20243782v1
The GenTegra GTR-STM and direct-into-PCR GenTegra GTR-STMdk saliva sample collection tubes are the only devices that eliminate dilution of virus levels in saliva samples, while providing a safe and convenient means to transport saliva samples at ambient conditions.
The dried transport media formulation in both of these devices incorporates the companys Active Chemical Protection (ACP) technology to provide substantial improvements in SARS-CoV-2 viral RNA stability, and RT-PCR process efficiency for COVID-19 saliva testing.
Direct-into-PCR, GTR-STMdk eliminates the need for expensive and time consuming RNA extraction, improving the turnaround time for reporting test results.